Aigen Investment Management LP Takes $861,000 Position in Novo Nordisk A/S $NVO

Aigen Investment Management LP acquired a new stake in Novo Nordisk A/S (NYSE:NVO) during the fourth quarter, Holdings Channel reports. The institutional investor acquired 16,917 shares of the company’s stock, valued at approximately $861,000.

Other hedge funds have also modified their holdings of the company. Godfrey Financial Associates Inc. acquired a new position in shares of Novo Nordisk A/S in the fourth quarter valued at about $25,000. WealthCollab LLC increased its holdings in shares of Novo Nordisk A/S by 93.5% in the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock valued at $27,000 after purchasing an additional 260 shares during the period. American National Bank & Trust acquired a new position in shares of Novo Nordisk A/S in the fourth quarter valued at about $28,000. Maseco LLP acquired a new position in shares of Novo Nordisk A/S in the fourth quarter valued at about $29,000. Finally, Jackson Grant Investment Advisers Inc. acquired a new position in shares of Novo Nordisk A/S in the fourth quarter valued at about $29,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts recently commented on NVO shares. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $41.00 target price (down from $63.00) on shares of Novo Nordisk A/S in a report on Monday, March 2nd. Weiss Ratings lowered Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, April 22nd. Citigroup reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a report on Tuesday, May 12th. Kepler Capital Markets lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Tuesday, February 24th. Finally, Wall Street Zen raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. Four analysts have rated the stock with a Buy rating, eighteen have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Novo Nordisk A/S has a consensus rating of “Hold” and a consensus price target of $65.56.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: UK regulators approved Novo Nordisk’s daily Wegovy pill, making it the first GLP-1 weight-loss tablet approved in the UK. That expands the company’s obesity franchise beyond injections and could open a new growth channel. UK approves Novo weight-loss pill to edge open European market
• Positive Sentiment: Several follow-up reports highlighted the UK approval as a milestone that could help Novo regain momentum in the obesity market and broaden access to Wegovy through private prescriptions. Novo Nordisk Wegovy pill becomes first daily GLP-1 weight-loss pill approved in the UK
• Positive Sentiment: Analysts also raised FY2026 EPS estimates slightly, signaling still-solid earnings expectations despite recent share-price weakness. Novo Nordisk A/S Trading Down 0.1%
• Neutral Sentiment: Some commentary on the “Wegovy pill” said the approval is encouraging but not yet enough to make certain investors buy, suggesting the market may want more proof of commercial impact before re-rating the stock. Novo Nordisk: Wegovy Pill Is Encouraging But Still Not Enough To Make Me Buy
• Negative Sentiment: Novo Nordisk disclosed an IT security incident involving unauthorized access to internal systems and potential data copying, which could pressure investor confidence even though the company said operations were not materially affected. Novo Nordisk hit by cyber incident, probes data breach
• Negative Sentiment: Another report said some U.S. employers may drop GLP-1 obesity-drug coverage in 2027, a potential headwind for long-term demand and reimbursement for Wegovy and rival products. Some US employers to drop coverage of GLP-1 obesity drugs in 2027 as use increases

Novo Nordisk A/S Stock Performance

Shares of NVO stock opened at $43.90 on Monday. The company has a market capitalization of $196.02 billion, a P/E ratio of 10.31, a P/E/G ratio of 3.92 and a beta of 0.78. The business’s 50 day moving average is $42.28 and its two-hundred day moving average is $46.00. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59. Novo Nordisk A/S has a 12-month low of $35.12 and a 12-month high of $81.44.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share (EPS) for the quarter. The company had revenue of $10.85 billion for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%. Analysts expect that Novo Nordisk A/S will post 3.45 EPS for the current fiscal year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.